|
Prof Carlo Gambacorti-Passerini talks about his research into bosutinib as a treatment for patients with Philadelphia chromosome–positive chronic phase chronic myeloid leukaemia. The trial compared bosutinib with imatinib, the current standard therapy for newly diagnosed patients, and patients in the bosutinib group were shown to respond almost twice as quickly as those treated with imatinib. Bosutinib produced similar levels of patient response as other tyrosine kinase inhibitors such as nilotinib and dasatinib but is associated with a lower toxicity profile. Prof Gambacorti-Passerini discusses this difference, talks about the benefits in terms of patient tolerance, safety levels and disease progression but also explains the adverse events encountered by the patients entered into this trial.
|
Video Length: 0
Date Found: February 18, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|